IP Library Granted Patent US 7,446,210
Granted Patent B2
US 7,446,210 · App. 11/257,208 · Granted Nov 4, 2008

Factor Xa compounds

Assignee: Janssen Pharmaceutica N.V.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,446,210
App. No.
11/257,208
Granted
Nov 4, 2008
Kind
B2
Abstract

The present invention is directed to novel compounds of Formula I: and forms and pharmaceutical compositions thereof, and the use thereof as inhibitors of Factor Xa.

Claims (31)

1. A compound having Formula I,

wherein

X is CF;

Z is CH;

A and B are independently selected from ethenyl, ethynyl, aryl, heteroaryl, 3-8 numbered carbocycle or 5-8 numbered heterocycle, each of which can be optionally substituted with 1, 2, 3 or 4 R groups;

K is selected from a bond, ethenyl, ethynyl, NR′, O, S, SO 2 or CO;

Ring P is pyrazole follows:

P 4 is substituted or unsubstituted benzene selected from:

wherein P 4 is optionally substituted with 1, 2, 3 or 4 R groups;

R 1 is selected from hydrogen, halogen, alkyl, haloalkyl, haloalkoxy, alkenyl, alkynyl, cycloalkyl, NCH 2 R, OCH 2 R, SCH 2 R, S(O) p CH 2 R, C(O)NR, OC(O)NR, NR a C(O)NR a CH 2 R, NR a C(O)OCH 2 R, NR a C(O)CH 2 R, hydroxyalkyl, cyano, nitro, trifluoromethyl or-CO 2 R;

provided that R 1 forms other than an N-halo, N-N, N-S, N-O, or N-CN bond;

R is selected from hydrogen, halogen, alkyl, alkenyl, alkynyl, cycloalkyl, hydroxy, alkoxy, haloalkyl, haloalkoxy, hydroxyalkyl, cyano, nitro, trifluoromethyl, —CO 2 R x , —CH 2 OR x or —OR x ,

R X is selected from hydrogen, C 1-6 alkyl; optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl or optionally substituted heteroaryl,

wherein optionally substituted alkyl, cycloalkyl, aryl and heteroaryl are each optionally substituted with one, two, three or four substituents selected from halogen, hydroxy, amino, mono or dialkyl amino, cyano, nitro, ester, acid or ether;

R′ is selected from hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted C 6-10 aryl, optionally substituted C 6-10 arylalkyl, optionally substituted heteroaryl or optionally substituted heteroaryl-alkyl,

wherein optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, C 6-10 aryl, the C 6-10 aryl portion of C 6-10 arylalky, heteroaryl and the heteroaryl portion of heteroaryl-alkyl are each optionally substituted with one, two, three or four substituents selected from halogen. hydroxy, carboxy, amino, monoalkylamino, dialkylamino, cyano, nitro, ester, acid or ether; and

R 2 is selected from hydrogen, C 1-4 alkyl or C 6-10 aryl; or a pharmaceutically acceptable salt or stereoisomer thereof.

2. The compound of claim wherein Ring P is:

R 1 is selected from alkyl, haloalkyl, C(O)NR or hydroxyalkyl.

3. The compound of claim 1 , wherein Ring P is:

P 4 is selected from:

4. The compound of claim 1 , wherein A is selected from aryl, heteroaryl, 3-8 numbered carbocycle or 5-8 numbered heterocycle.

5. The compound of claim 4 , wherein A is selected from:

6. The compound of claim 1 , wherein K is selected from a bond, ethynyl or NR′.

7. The compound of claim 1 , wherein B is selected from aryl, heteroaryl, 3-8 numbered carbocycle or 5-8 numbered heterocycle.

8. The compound of claim 7 , wherein B is selected from:

9. The compound of claim 1 , wherein the compound is an isolated form thereof.

10. The compound of any-of- claim 1 , wherein the form of said compound is a pharmaceutical composition or medicament comprising an effective amount of one or more of said compound.

11. The pharmaceutical composition of claim 10 , wherein the composition further comprises an effective amount of the compound and a pharmaceutically acceptable carrier.

12. A process for preparing a pharmaceutical composition comprising the step of admixing a compound of claim 1 and a pharmaceutically acceptable carrier.

13. The pharmaceutical composition of claim 10 , wherein the effective amount of the compound is in a range of from about 0.001 mg/kg to about 300 mg/kg of body weight per day.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 24, 2006
From: LU, TIANBAO; THIEU, THO V.; LEE, YU-KAI; PARKS, DANIEL J.; MARKOTAN, THOMAS P.; PAN, WENXI; MILKIEWICZ, KAREN; PLAYER, MARK R.
To: JANSSEN PHARMACEUTICA N.V.
Reel/Frame 018121/0715 →
Continuity (2)
Provisional Application 6062215600 · Oct 26, 2004
Related Publication 20060199809A1 · Sep 7, 2006